Greenphire, the global leader in financial software for clinical trials, today announced that its CEO, Jim Murphy, will co-present alongside Lazarex Cancer Foundation Founder, Dana Dornsife, at the Society for Clinical Research Sites (SCRS)'s annual Global Oncology Site Solutions Summit.
| KING OF PRUSSIA, Pa., Jan. 30, 2020 /PRNewswire/ -- Greenphire, the global leader in financial software for clinical trials, today announced that its CEO, Jim Murphy, will co-present alongside Lazarex Cancer Foundation Founder, Dana Dornsife, at the Society for Clinical Research Sites (SCRS)'s annual Global Oncology Site Solutions Summit. The presentation, “Removing Financial Toxicity from Oncology Clinical Trials Through Patient Reimbursement Programs,” will center on the direct impact reimbursements have on recruitment and retention rates in these specialized studies. Under enrollment in oncology studies has a downstream effect of delaying study completion and increasing the cost and time it takes to bring new therapies to market. Less than five percent of eligible patients participate in oncology clinical trials and that number is even lower among low income and diverse patient populations. Out-of-pocket costs, travel logistics and time are frequently cited as the top barriers to enrollment and retention. “Greenphire and Lazarex are aligned in the mission to reduce patient participation barriers and improve clinical trial access,” said Murphy. “This issue is about more than covering costs, it’s about streamlining processes and providing patients with peace of mind. I look forward to discussing bottom up and top down strategies that sponsors and investigative sites can use to increase participation and reduce barriers.” Scheduled for Friday, January 31, at 2:30 pm, attendees will learn about evolving models, tools and regulations aimed at improving access and retention and increasing patient convenience. Key topics will include:
“Collaborating with the Greenphire team has helped our organization realize the goal of eliminating burdens for patients in an efficient and scalable way,” explained Dornsife. “Greenphire is the expert in this space, and we have seen first-hand the enormous impact its reloadable debit card technology, ClinCard, has had for the patients we support and improvement in the efficiency of our organization. We are excited to share our learnings with top industry sponsors, sites and CROs.” The event, occurring in Austin, Texas this year from January 31st through February 1st, will serve as an opportunity to unite sites, sponsors and CROs in order to propel cancer research to a new level. For full details, visit http://oncologysitesolutionssummit.com/ About Greenphire About Lazarex Cancer Foundation Media Contact
SOURCE Greenphire |
View original content:
